Abstract:beta-Glucan particles (GPs) are purified Saccharomyces cerevisiae cell walls treated so that they are primarily beta 1,3-D-glucans and free of mannans and proteins. GPs are phagocytosed by dendritic cells (DCs) via the Dectin-1 receptor, and this interaction stimulates proinflammatory cytokine secretion by DCs. As the hollow, porous GP structure allows for high antigen loading, we hypothesized that antigen-loaded GPs could be exploited as a receptor-targeted vaccine delivery system. Ovalbumin (OVA) was electrostatically complexed inside the hollow GP shells (GP-OVA). Incubation of C57BL/6J mouse bone marrow-derived DCs with GP-OVA resulted in phagocytosis, upregulation of maturation markers, and rapid proteolysis of OVA. Compared with free OVA, GP-OVA was > 100-fold more potent at stimulating the proliferation of OVA-reactive transgenic CD8(+) OT-I and CD4(+) OT-II T cells, as measured by in vitro [H-3] thymidine incorporation using DCs as antigen-presenting cells. Next, immune responses in C57BL/6J mice following subcutaneous immunizations with GP-OVA were compared with those in C57BL/6J mice following subcutaneous immunizations with OVA absorbed onto the adjuvant alum (Alum/OVA). Vaccination with GP-OVA stimulated substantially higher antigen-specific CD4(+) T-cell lymphoproliferative and enzyme-linked immunospot (ELISPOT) responses than that with Alum/OVA. Moreover, the T-cell responses induced by GP-OVA were Th1 biased (determined by gamma interferon [IFN-gamma] ELISPOT assay) and Th17 biased (determined by interleukin-17a [IL-17a] ELISPOT assay). Finally, both the GP-OVA and Alum/OVA formulations induced strong secretions of IgG1 subclass anti-OVA antibodies, although only GP-OVA induced secretion of Th1-associated IgG2c antibodies. Thus, the GP-based vaccine platform combines adjuvanticity and antigen delivery to induce strong humoral and Th1- and Th17-biased CD4(+) T-cell responses.IMPORTANCE Most licensed vaccines work by promoting protective antibody responses. However, for many infectious diseases, antibody-mediated protection appears to play a relatively minor role, and vaccination has met with limited success. While live-attenuated organisms generally elicit T-cell responses, their use in vaccines is limited by the potential for causing disease. Thus, there is an urgent need for new vaccine platforms that deliver antigens in such a manner as to promote strong T-cell-mediated responses. Here we designed a novel vaccine platform consisting of yeast-derived beta-glucan particles (GPs) that combines antigen delivery and adjuvant activity. GPs loaded with the model antigen ovalbumin (OVA) stimulated robust humoral and T-cell responses in mice. In addition, the cellular response was Th1 and Th17 biased. This work has implications for the design of vaccines that stimulate biased T-cell responses as well as for understanding how immunity to fungal pathogens develops.

Synergistic Effect of Dual Targeting Vaccine Adjuvant with Aminated Β-Glucan and CpG-oligodeoxynucleotides for Both Humoral and Cellular Immune Responses

Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8 + T Cell Responses

Dual TLR Agonist Nanodiscs As a Strong Adjuvant System for Vaccines and Immunotherapy

The Orientation of CpG Conjugation on Aluminum Oxyhydroxide Nanoparticles Determines the Immunostimulatory Effects of Combination Adjuvants

Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion

In vitro and in vivo investigation of chitosan–polylysine polymeric nanoparticles for ovalbumin and CpG co-delivery

The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization

Self-adjuvanting Polymeric Nanovaccines Enhance IFN Production and Cytotoxic T Cell Response.

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination

A Toll-like Receptor-Activating, Self-Adjuvant Glycan Nanocarrier

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release

Universal and Translational Nanoparticulate CpG Adjuvant

Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses

Robust Stimulation Of Humoral And Cellular Immune Responses Following Vaccination With Antigen-Loaded Beta-Glucan Particles

The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists

Synthetic Innate Defense Regulator Peptide Combination Using Cpg Odn As A Novel Adjuvant Induces Long-Lasting and Balanced Immune Responses

pH Responsive Poly(Amino Acid) Nanoparticles as Potent Carrier Adjuvants for Enhancing Cellular Immunity

Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses